Last $63.21 USD
Change Today +0.70 / 1.12%
Volume 315.8K
STE On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

steris corp (STE) Snapshot

Open
$62.65
Previous Close
$62.51
Day High
$63.38
Day Low
$62.28
52 Week High
11/13/14 - $65.03
52 Week Low
02/5/14 - $39.90
Market Cap
3.8B
Average Volume 10 Days
444.9K
EPS TTM
$2.44
Shares Outstanding
59.4M
EX-Date
11/24/14
P/E TM
25.9x
Dividend
$0.92
Dividend Yield
1.39%
Current Stock Chart for STERIS CORP (STE)

steris corp (STE) Related Businessweek News

No Related Businessweek News Found

steris corp (STE) Details

STERIS Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company’s Healthcare segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers; liquid chemical sterilant processing systems; washer/disinfector systems; general and specialty surgical tables; surgical and examination lights; equipment management systems; operating room storage cabinets; warming cabinets; scrub sinks; gastrointestinal endoscopy accessories; connectivity solutions, such as operating room integration, workflow, patient tracking, and instrument management; cleaning chemistries and sterility assurance products; and cleansing products, including hard surface disinfectants, and skin care and hand hygiene solutions. This segment also provides maintenance programs and repair services; sterilization and surgical management consulting services; information management and decision support services; and other support services comprising construction and facility planning, engineering support, device testing, customer education, hand hygiene process excellence, asset management/planning, and the sale of replacement parts. Its Life Sciences segment offers formulated cleaning chemistries, vaporized hydrogen peroxide generators; sterilizers; and high-purity water equipment, as well as various preventive maintenance programs and repair services. The company’s STERIS Isomedix Services segment provides contract processing services using gamma irradiation and ethylene oxide technologies; and microbial reduction services. It sells its products to end users, dealers, and distributors. The company was formerly known as Innovative Medical Technologies and changed its name to STERIS Corporation in 1987. STERIS Corporation was founded in 1985 and is headquartered in Mentor, Ohio.

6,000 Employees
Last Reported Date: 05/29/14
Founded in 1985

steris corp (STE) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $788.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $351.8K
Senior Vice President and Group President of ...
Total Annual Compensation: $401.6K
Senior Vice President and Group President of ...
Total Annual Compensation: $321.3K
Senior Vice President of Infection Prevention...
Total Annual Compensation: $312.6K
Compensation as of Fiscal Year 2014.

steris corp (STE) Key Developments

Steris Corporation Declares Quarterly Dividend, Payable on December 23, 2014; Announces Unaudited Consolidated Financial Results for the Second Quarter and First Half Year Ended September 30, 2014; Revises Financial Outlook for Fiscal 2015

The Steris Corp. Board of Directors has authorized a quarterly dividend of $0.23 per common share. The dividend is payable December 23, 2014 to shareholders of record at the close of business on November 26, 2014. The company announced financial results for the second quarter and first half year ended September 30, 2014. As reported, fiscal 2015 second quarter revenue increased 21% to $462.7 million compared with $383.8 million in the second quarter of fiscal 2014. As reported, net income was $31.0 million, or $0.52 per diluted share, compared with net income of $29.7 million, or $0.50 per diluted share in the second quarter of fiscal 2014. On an adjusted basis, net income for the second quarter of fiscal 2015 was $40.6 million, or $0.68 per diluted share, compared with adjusted net income of $32.6 million, or $0.55 per diluted share in the same prior year period. Second quarter revenue grew 21% driven by acquisitions as well as strong organic growth in both Healthcare and Isomedix. The company was able to leverage that revenue growth to drive a 24% improvement in adjusted earnings per diluted share. Operating income was $53,423,000 against $50,300,000 a year ago. Adjusted operating income was $68,969,000 against $55,018,000 a year ago. Net income attributable to common shareholders was $31,004,000 against $29,743,000 a year ago. Adjusted net income attributable to common shareholders was $40,565,000 against $32,621,000 a year ago. Capital spending was $13.2 million in the quarter, while depreciation and amortization was $27.4 million. Net cash provided by operations for the first six months of fiscal 2015 was $104.9 million, compared with $80.0 million in the same period last year. Free cash flow for the first half of fiscal 2015 was $69.2 million, compared with $32.9 million in the first half of last year. The increase in free cash flow is primarily due to the impact of working capital improvements and lower capital expenditures. For the first half, the company reported revenue of $875,372,000 against $751,414,000 a year ago. Income from operations was $97,591,000 against $91,312,000 a year ago. Net income was $55,541,000 against $62,060,000 a year ago. Diluted earnings per share were $0.93 against $1.04 a year ago. Purchases of property, plant, equipment, and intangibles, net were $36,527,000 against $47,110,000 a year ago. Adjusted operating income was $124,940,000 against $101,080,000 a year ago. Net income attributable to common shareholders was $55,541,000 against $62,060,000 a year ago. Adjusted net income attributable to common shareholders was $72,613,000 against $58,774,000 a year ago. Based upon current trends, the company is affirming its original revenue growth outlook for fiscal 2015 of 15-17%. However, given the strength in the first half of the year and anticipated second half performance, the company now anticipates adjusted earnings per diluted share in the range of $2.86 to $2.91 for the full fiscal year, which is at the high-end of the original outlook. The outlook excludes any potential impact from the proposed Synergy Health acquisition. The company reiterates continue to expect to achieve both the annual pretax cost savings of $30 million or more and to reduce effective tax rate to approximately 25% of earnings for the combined businesses. For fiscal year ending March 31, 2015, the company expects free cash flow at $135,000, cash flow from operation activities expected to be at $230,000 and purchase of property, plant and equipment at $95,000. The company continues to anticipate a full year effective tax rate of approximately 35%, which does include the assumed renewal of tax extenders.

Steris Corp. to Report Q2, 2015 Results on Nov 05, 2014

Steris Corp. announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Nov 05, 2014

Steris Corp., Q2 2015 Earnings Call, Nov 05, 2014

Steris Corp., Q2 2015 Earnings Call, Nov 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STE:US $63.21 USD +0.70

STE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Catalent Inc $28.72 USD +0.87
Hill-Rom Holdings Inc $46.06 USD +0.10
Teleflex Inc $118.95 USD +0.56
West Pharmaceutical Services Inc $52.11 USD +0.17
View Industry Companies
 

Industry Analysis

STE

Industry Average

Valuation STE Industry Range
Price/Earnings 30.8x
Price/Sales 2.2x
Price/Book 3.5x
Price/Cash Flow 30.6x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STERIS CORP, please visit www.steris.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.